These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20329620)

  • 1. [Consideration about data management and biostatistics analysis from a FDA's botanical drug approval case].
    Tang JY; Huang FH; Zhu FP
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Nov; 29(11):1035-9. PubMed ID: 20329620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Discussion about traditional Chinese medicine pharmacokinetics study based on first botanical drug approved by FDA].
    Huang F
    Zhongguo Zhong Yao Za Zhi; 2010 Apr; 35(7):932-5. PubMed ID: 20575403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The US Food and drug administration: drug information resource for formulary recommendations.
    Marchand HC; Ros BJ; Fine AM; Kremzner ME
    J Manag Care Pharm; 2012; 18(9):713-8. PubMed ID: 23206214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FDA's risk/benefit calculus in the approvals of Qsymia and Belviq: treating an obesity epidemic while avoiding another fen-phen.
    Azebu LM
    Food Drug Law J; 2014; 69(1):87-111, ii-iii. PubMed ID: 24772687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical trademarks: navigating through the FDA's pilot program.
    Ferrer E
    Drug News Perspect; 2010 Jun; 23(5):333-6. PubMed ID: 20603657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
    Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
    Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing patient autonomy through peer review to replace the FDA's rigorous approval process.
    Caplan A
    Health Aff (Millwood); 2012 Oct; 31(10):2236-40. PubMed ID: 23048103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FDA's generic-drug approval process: similarities to and differences from brand-name drugs.
    Kefalas CH; Ciociola AA
    Am J Gastroenterol; 2011 Jun; 106(6):1018-21. PubMed ID: 21637264
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmaceutical industry perspective on risk evaluation and mitigation strategies: manufacturer take heed.
    Nicholson S; Peterson J; Yektashenas B
    Expert Opin Drug Saf; 2012 Mar; 11(2):299-314. PubMed ID: 22233294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How drugs are developed and approved by the FDA: current process and future directions.
    Ciociola AA; Cohen LB; Kulkarni P;
    Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study.
    Kesselheim AS; Wang B; Franklin JM; Darrow JJ
    BMJ; 2015 Sep; 351():h4633. PubMed ID: 26400751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2014 in review: FDA approval of new drugs.
    Kinch MS
    Drug Discov Today; 2017 Apr; 22(4):620-624. PubMed ID: 26100738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA policy on unapproved drug products: past, present, and future.
    Chhabra R; Kremzner ME; Kiliany BJ
    Ann Pharmacother; 2005; 39(7-8):1260-4. PubMed ID: 15956239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of FDA's Accelerated Approval Program Performance December 1992-December 2021.
    Beakes-Read G; Neisser M; Frey P; Guarducci M
    Ther Innov Regul Sci; 2022 Sep; 56(5):698-703. PubMed ID: 35900722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When is a medical product too risky? An interview with FDA's top drug official. Interview by Tamar Nordenberg.
    Woodcock J
    FDA Consum; 1999; 33(5):8-11, 13. PubMed ID: 10522164
    [No Abstract]   [Full Text] [Related]  

  • 17. Characteristics of rare disease marketing applications associated with FDA product approvals 2006-2010.
    Pariser AR; Slack DJ; Bauer LJ; Warner CA; Tracy LA
    Drug Discov Today; 2012 Aug; 17(15-16):898-904. PubMed ID: 22564486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scientific and Regulatory Approach to Botanical Drug Development: A U.S. FDA Perspective.
    Wu C; Lee SL; Taylor C; Li J; Chan YM; Agarwal R; Temple R; Throckmorton D; Tyner K
    J Nat Prod; 2020 Feb; 83(2):552-562. PubMed ID: 31977211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The year's new drugs & biologics 2015 - part II:Trends and highlights that marked a complicated year.
    Graul AI; Cruces E; Dulsat C; Tracy M
    Drugs Today (Barc); 2016 Feb; 52(2):131-63. PubMed ID: 27092342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk management and intrusions on medical practice: striking a balance.
    Enzi MB; Kennedy EM
    Health Aff (Millwood); 2007; 26(3):678-80. PubMed ID: 17485743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.